Objective: To determine serum zinc (Zn) level among cystic fibrosis (CF) patients with homozygous CFTR I1234V mutation associated with pancreatic sufficiency (PS). Methods: A cross-sectional study was conducted including both pediatric and adult CF patients. Data on age, weight, height, body mass index (BMI), BMI Z-score, FEV1, and chronic Pseudomonas aeruginosa infection were collected. Serum Zn, albumin, and total proteins were measured and analyzed.
Introduction
Cystic fibrosis (CF) is one of the most common inherited diseases among Caucasians (1) . It is caused by mutation in thecystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a transmembrane glycoprotein (2, 3) . One of the main consequences of mutations in the CFTR gene is a dysfunction of ion channels resulting in elevated sweat This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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The Clinical Respiratory Journal ORIGINAL ARTICLE chloride concentrations, pancreatic insufficiency (PI) and progressive lung disease (4) . Over 90% of CF patients are PI, whereas the remaining 10%-15% of patients are pancreatic sufficiency (PS) (5, 6) . Pseudomonas aeruginosa is one of the primary pathogens in patients with CF (7) . CF patients infected with P. aeruginosa have increased pulmonary disease and experience more rapid decline in pulmonary function than patients who are P. aeruginosa culture and antibody negative (8) .
Zn is a mineral involved in more than 300 functions in the body (9) . It is an integral part of the structure and function of many biological enzymes and a regulator of ion transporters relevant to pulmonary function and disease in CF and other pulmonary disorders (10) (11) (12) (13) . Zn is also known to exhibit powerful antioxidant activity in several organ systems including the lungs (10) (11) (12) (13) . It is important for the development and function of cells mediating nonspecific immunity such as neutrophils, macrophages, and natural killer cells (14) .
Zn deficiency has been observed in a subset of patients with CF, especially those with malabsorption and impaired growth. Several studies evaluating the Zn status of CF patients were based on serum Zn concentrations. The results, however, are contradictory (15) (16) (17) (18) (19) . Since symptoms of Zn deficiency are nonspecific and overlap those of CF, detection of clinical deficiency appears difficult and therefore we based on measurement of serum Zn levels (20) .
CFTR I1234V mutation is one of the common mutations among Arabs in the Gulf region and associated with PS. This mutation belongs to a large kindred Arab tribe, consisting of a number of families who share a common ancestry and culture (21) (22) (23) . Previous studies showed that CF patients with CFTR I1234V mutation are homozygous in this Arab tribe, with high consanguinity, have normal bowel motion and normal levels of faecal elastase 1 (21, 23). As Zn is an important element in the body and had a fundamental role in cellular metabolism, with profound effects on the immune system so we hypothesize and investigate whether there is an effect of Zn on CF lung and their association with chronic P. aeruginosa colonization among CF patients with this mutation. Zinc status has not been reported well in these CF patients with this mutation. The primary objective of this study was to measure serum Zn level among CF patients with homozygous CFTR I1234V mutation associated with PS and the secondary aim was to compare growth, pulmonary function and frequency of P. aeruginosa colonization in CF patients with and without Zn deficiency.
Materials and methods

Study design and population
A cross-sectional study was conducted including both pediatric and adult CF patients with the CFTR I1234V mutation belonging to a large kindred Arab tribe and other CFTR mutations attending the CF clinic at Hamad Medical Corporation (HMC), Doha, Qatar during the period of April 2013-November 2013. Healthy subjects belonging to the same Arab tribe were selected in order to assess only their Zn levels. The diagnosis of CF was based on one or more clinical features consistent with CF, positive family history of CF in siblings and close relatives, elevated sweat chloride (>60 mmol/L) on two separate occasions in addition to the presence of two disease-causing mutations in the CFTR gene. Inclusion criteria were all of the CF patients had no respiratory infections nor exacerbation for more than 4 weeks prior to enrollment. Exclusion criteria included all CF patients who were vegetarian, those with significant liver disease as defined by clinical findings of portal hypertension or cirrhosis or AST, ALT, or GGT > 2 the upper limit of normal, gall bladder disease, diabetes mellitus requiring insulin therapy, renal failure, malignancies, or collagen vascular disease or taking medications known to have an effect zinc status such as oral contraceptives or use of oral immunosuppressive drugs (steroids and nonsteroid antiinflammatory drugs). This study was reviewed and approved by the local ethics committee at Hamad Medical Corporation (Ref#12226/12).
All CF patients were assessed based on the medical history including frequent pulmonary exacerbation, and whether their lower lung secretions harbor chronic P. aeruginosa colonization.
Anthropometric measurements
Anthropometric measurements were performed using digital electronic platform scale and standing height measurement without shoes using a stadiometer. Body mass index (BMI) was calculated by dividing weight in kg by height squared in meters {weight (Kg)/(height (m)) 2}. The standard deviation [Z] score for BMI was calculated and adjusted for age and gender. Spirometry was obtained by standard methods in patients old enough to perform adequately (24) . The highest of three technically appropriate measurements was recorded. Forced vital capacity (FVC; in liters) and (% predicted), forced expiratory volume in 1 s (FEV1; in liters) and (% predicted), and FEV1/FVC were measured using a flow-sensing spirometer (Sensor Medicus Model V6200, Germany).
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Biochemical analysis
Biochemical analysisfor serum Zn: 5 mL of whole blood in trace metal free tube was collected from participants (non fasting blood sample). After clotting and centrifugation, serum was stored at 2608C until analysis. Zn levels were determined by Flame Atomic Absorption spectrophotometer using Thermo electron corporation analyzer. The tests performed by an experience senior laboratory technician. Results were compared to healthy controls from the same tribe. The normal reference range for Zn is 0-10 years: 0.60-1.20 mcg/mL and for > or =11 years: 0.66-1.10 mcg/mL (25, 26) . Albumin and total proteins were measured using Bromcresol Green method (BCG Method).
Statistical analysis
Categorical data were expressed as a frequency along with percentage and continuous data values presented in mean 6 standard deviation and median and range. Descriptive statistics were used to summarize all demographic anthropometric, serum Zn, and spirometric measures and other characteristics of the participants. Unpaired t and Mann-Whitney U-tests were applied to compare mean of quantitative variables between the two independent groups (normal Zn levels and deficient Zn levels). Associations between two or more qualitative variables were assessed using chi-squared and Yates corrected chi-squared tests. Pearson's correlation coefficient was used to assess the strength of linear relationship between two or more quantitative variables. A two-sided P value <0.05 was considered to be statistically significant. All statisticalanalyses were done using the statistical package SPSS 19.0 (SPSS Inc. Chicago, IL).
Results
Fifty-three CF patients (31 females, 22 males) were studied, and their clinical characteristics are summarized in Table 1 . The mean age was 15.1 6 9.1 years with median 15 and range was 2-49 years. Forty-five CF patients with homozygous CFTR I1234V mutation associated with PS. The remaining eight CF patients with non CFTR I1234V mutation and PI. All CF patients with PI were taking pancreatic enzyme replacement therapy (PERT) and standard multivitamins with Zn content. Eight of 45 CF patients with PS were on multivitamins.
The mean plasma Zn of 0.78 6 0.15 mcg/mL was ranged 0.48-1.04 (Table1). Seven (13.2%) patients with CFTR I1234V and PS had low Zn levels, below 0.6 mcg/ mL, when standard reference values were used for classification. There was a negative correlation between age and Zn levels, however it was not statically significant (r 5 20.223; P > 0.05) (Fig. 1) . The mean height SDS was 20.76 6 0.97 and BMI Z-score was 0.59 6 1.4. Thirty-nine patients were able to perform spirometry adequately, that include all the seven CF patients with Zn-deficient and 32 CF patients with normal Zn level. The mean FEV1 (% predicted) was 79.1 6 22.2 and the mean FVC (%predicted) was 83.4 6 20.6%. All CF deficient Zn were not taking multivitamins. Patients mean age in the Zn deficient group was significantly higher, 23.0 6 12.2 years compared to that observed in the normal Zn levels group, 13.9 6 8.1 years (P 5 0.013) in Table 2 . The mean albumin was observed to be higher among zinc sufficient group compared to Zn deficient group (43.8 6 3.5 vs 40.4 6 3.6; P 5 0.027). The mean FEV1 (% predicted) in the Zn deficient group was found to be lower, 66.5 6 29.6% compared to patients with normal Zn levels, 81.4 6 20.4% (P 5 0.133). Persistent P. aeruginosa colonization was more prevalent in Zn deficient group. BMI Z-score, FEV1%, FVC%, and FEV1/FVC were positively associated with Zn levels. Forty-five healthy subjects belonging to the same Arab tribe were selected in order to assess their Zn levels and their mean plasma Zn of 0.84 6 0.11 mcg/mL (range 0.65-1.1 mcg/mL) with mean age 20.4 6 10.1 years (range 6-40 years).
Discussion
In this study, we evaluated the zinc status in a selected group of CF patients associated with PS. Hypozincemia was diagnosed in seven CF patients with homozygous CFTR I1234V mutation, although, they did not have any specific symptoms of Zn deficiency. However, they had more frequent pulmonary exacerbations and more frequently harbor pseudomonas colonization.
Research studies in humans and in cell models point to the useful effect of Zn in reducing inflammatory cytokines at the mRNA level and involves inhibition of NF-kB activation (27) . P. aeroginosa in subjects with CF and in CF animal models can lead to activation of the NF-kB pathway and overproduction of adhesion molecules, inflammatory cytokines (IL-1b, TNF-a, IL-6, and IL-8), and oxidative stress molecules, which in turn continue to provide stimulus for further NF-kB activation and the relentless vicious cycle (28) (29) (30) . A recent study provided evidence that 30 mg/day supplemental Zn was associated with reduction in the number of days of oral antibiotics used to treat respiratory tract infections and marginal reduction in the level of plasma inflammatory cytokines in children with CF (31) . A number of investigators have reported conflicting relationships between Zn status, malabsorption, impaired growth, and pulmonary function in CF patients (16-19, 32, 33) . Few studies found no correlation between Zn levels and nutritional or pulmonary status (17, 18) . Others reported abnormal Zn status in certain patients with CF especially those with moderate to severe growth retardation and severe pulmonary disease as compared with those without growth failure and with moderate pulmonary disease (33) . In this study, there were association between Zn levels and BMI Z score and FEV1, however, it was not statistically significant (P > 0.05). Zn deficient CF patients have lower BMI Z score, FEV1 and harbor more P. aeruginosa colonization compared to those with normal Zn levels. In a recent retrospective study reported the occurrence of Zn deficiency in CF adults, highlighting the fact that CF subjects with low Zn status exhibit worse pulmonary function and a higher prevalence of impaired bone and glycemic status but they did not report whether these patients were colonized with P. aeruginosa colonization or other organisms (34) . It is to be noted that that the primary analysis was not to determine the predictive values of different confounders or related factors associated with serum Zn levels and also due to the limited number of patients in the Zn deficient group, exploration for any multivariate regression analysis could not be possible and performed.
Because Zn plays an important role in immunity, the decreased serum Zn in patients with decreased pulmonary function could enhance infection, leading to a vicious circle or could be a result of decreased immunity in Zn deficient CF patients that may lead to frequent pulmonary exacerbation specialty among those with chronic P. aeruginosa leading to decreased pulmonary function. Eight PI CF patients in this study had normal Zn levels and this may be related to multivitamin intake containing Zn and on PERT that improves Zn absorption. The group of Hambidge (35) showed a decreased fractional absorption of Zn in PI CF though pancreatic enzyme replacement has been shown to improve zinc absorption in children (35) .
The limitation of this study is the low numbers of CF patients. However, an important finding is that seven zinc deficient CF patients were all PS and all the eight PI CF patients had normal Zn levels.
Conclusion
Zn deficiency can occur in patients with CF and PS and appeared not to be associated with PI. Further investigations are needed to understand the role of Zn in mediating pulmonary function in CF subjects and to explore the association between zinc status and clinical outcomes of CF patients such as cystic fibrosis related diabetes, bone, kidney, and liver diseases.
